Zealand Pharma A/S at Jefferies Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Lucy Codrington - Jefferies - Analyst : Great. Thank you for. I'll let you take your seat. So I think it makes sense to start with the obesity pipeline, given the excitement surrounding that. And you mentioned the headline data for the BI 456906. How did that data sit versus your expectations, and what you're looking at in terms of the competitive market? And what additional data can we expect to ADA?

Question: Lucy Codrington - Jefferies - Analyst : So you touched on tolerability with that. How important is titration to achieving a good tolerability profile for this asset? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 08, 2023 / 12:30PM, ZELA.CO - Zealand Pharma A/S at Jefferies Healthcare Conference And then secondly, comparing it to other GLP-1 glucagon agonist, how important is the ratio? And how do you compare to competitors?

Question: Lucy Codrington - Jefferies - Analyst : Great. And just on the ratio. Could you comment on that and how you sit versus the other products in development?

Question: Lucy Codrington - Jefferies - Analyst : And so you've got a broad obesity pipeline. Which one is most exciting for Zealand, would you say?

Question: Lucy Codrington - Jefferies - Analyst : Great. And what can we expect from any additional data presented to the amylin asset at ADA?

Question: Lucy Codrington - Jefferies - Analyst : Great. And then you mentioned, your dapiglutide, the GLP-1, GLP-2. As far as I'm aware, you're the only one and developing an asset like this. Why do you think that is, and what are the additional benefits of combining the two together?

Question: Lucy Codrington - Jefferies - Analyst : And finally, on the obesity pipeline, what is your partnering strategy given you have three assets that are wholly-owned?

Question: Lucy Codrington - Jefferies - Analyst : Great. Unless there's any questions from the audience, we move onto dasiglucagon and CHI. You're planning to file that imminently. How clinically meaningful would you say the results were that you saw in the trial? And I guess, how important is that, given I assume, IV glucose is a relatively cheap option for these patients?

Question: Lucy Codrington - Jefferies - Analyst : Okay. And then just moving on to glepaglutide. The twice-weekly formulation hit the primary endpoint and there is a once weekly formulation in development, but that doesn't use an auto-injector. What's been the feedback from physicians and KOLs about a, a twice-weekly versus the current once-weekly? And then b, how important is twice-weekly versus once-weekly when you throw an auto-injector into the mix?

Question: Lucy Codrington - Jefferies - Analyst : Great. And I think with that, we have run down the clock. So I'd like to take this opportunity to thank Henriette for that presentation. And thank your audience for your attendance, and we'll move on to the next track.